
Aprutumab
CAS No. 1634620-63-5
Aprutumab( —— )
Catalog No. M36658 CAS No. 1634620-63-5
Aprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize antibody-drug conjugates.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 869 | Get Quote |
![]() ![]() |
5MG | 1539 | Get Quote |
![]() ![]() |
10MG | 2071 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameAprutumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize antibody-drug conjugates.
-
DescriptionAprutumab?(BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has?the?potential?for?solid tumors research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetFGFR
-
RecptorFGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1634620-63-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Anette Sommer, et al. Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors. Cancer Res (2016) 76 (21): 6331–6339.?
molnova catalog



related products
-
Amlexanox
Amlexanox (AA673; CHX3673) is a specific inhibitor of IKKε and TBK1; inhibition of IKKε and TBK1 activity as determined by MBP phosphorylation showing an IC50 of approximately 1–2 μM.
-
Pemigatinib (INCB054...
Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor.
-
Dovitinib lactate
A novel, multitargeted RTK inhibitor of class III, IV, and V RTKs.